Descripción del proyecto
Nuevo tratamiento de politerapia para la tuberculosis
La tuberculosis (TB) sigue siendo la enfermedad infecciosa más mortal del planeta y la TB multirresistente representa una amenaza grave para la salud mundial. Las opciones de tratamiento son limitadas y a menudo se relacionan con numerosos efectos secundarios generados por los fármacos. El objetivo general del proyecto RespiriTB, financiado con fondos europeos, es encontrar nuevos fármacos candidatos para una politerapia eficaz contra la TB y la TB multirresistente. La politerapia estará dirigida al metabolismo energético de la «Mycobacterium tuberculosis» (Mtb) mediante el uso de inhibidores recientemente descubiertos de la vía respiratoria de Mtb. También se dirigirá a los factores de los hospedadores que son vitales para la supervivencia intracelular de Mtb. El proyecto presenta un plan exhaustivo para descubrir nuevas estrategias con las que combatir la TB, acortar el tiempo de tratamiento y reducir las incidencias de farmacorresistencia.
Objetivo
Despite recent progress in biomedical research, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is still the world’s leading infectious disease killer worldwide. In addition, multi-drug TB is the largest single contributor to anti-microbial resistance and poses a serious threat to global health. Treatment options are limited, and expensive, recommended medicines are not always available in many countries, and patients experience many adverse effects from the drugs. Moreover, due to the long treatment duration, compliance is low leading to more AMR in TB. Thus, there is an acute need for the development of a novel combination regimen with an indication for effective, shorter, and safer treatment of all forms of TB. The overall objective of RESPIRI-TB is to find new drug candidates as potential components of a new, more efficient combination drug regimen against TB that is less prone to resistance and allows shortening of treatment duration for TB, and multidrug-resistant TB. Such a drug combination will synergistically target the energy metabolism of Mtb or complementary targets. To achieve this, we will advance recently discovered inhibitors of the Mtb respiratory pathway. In addition, we will target the Mtb specific molecular mechanism that reduces reactive oxygen species in the cell. Finally, we will also target host-factors that are essential for the intracellular survival of Mtb. Together, we present a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce chances of drug resistance.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programa(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2018-16-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
2333 ZA Leiden
Países Bajos